Le informazioni sugli articoli di fonte ISI sono coperte da copyright

Per ulteriori informazioni selezionare i riferimenti di interesse.

1. Liu, YQ; Kyle, E; Patel, S; Housseau, F; Hakim, F; Lieberman, R; Pins, M; Blagosklonny, MV; Bergan, RC
   Prostate cancer chemoprevention agents exhibit selective activity against early stage prostate cancer cells
   PROSTATE CANCER AND PROSTATIC DISEASES
   
   Y.Q. Liu et al., "Prostate cancer chemoprevention agents exhibit selective activity against early stage prostate cancer cells", PROSTATE C, 4(2), 2001, pp. 81-91
2. Bergan, RC; Waggle, DH; Carter, SK; Horak, I; Slichenmyer, W; Meyers, M
   Tyrosine kinase inhibitors and signal transduction modulators: Rationale and current status as chemopreventive agents for prostate cancer
   UROLOGY
   
   R.C. Bergan et al., "Tyrosine kinase inhibitors and signal transduction modulators: Rationale and current status as chemopreventive agents for prostate cancer", UROLOGY, 57(4A), 2001, pp. 77-80
3. Liu, YQ; Kyle, E; Lieberman, R; Crowell, J; Kelloff, G; Bergan, RC
   Focal adhesion kinase (FAK) phosphorylation is not required for genistein-induced FAK-beta-1-integrin complex formation
   CLINICAL & EXPERIMENTAL METASTASIS
   
   Y.Q. Liu et al., "Focal adhesion kinase (FAK) phosphorylation is not required for genistein-induced FAK-beta-1-integrin complex formation", CLIN EXP M, 18(3), 2000, pp. 203-212
4. Bergan, RC; Reed, E; Myers, CE; Headlee, D; Brawley, O; Cho, HK; Figg, WD; Tompkins, A; Linehan, WM; Kohler, D; Steinberg, SM; Blagosklonny, MV
   A phase II study of high-dose tamoxifen in patients with hormone-refractory prostate cancer
   CLINICAL CANCER RESEARCH
   
   R.C. Bergan et al., "A phase II study of high-dose tamoxifen in patients with hormone-refractory prostate cancer", CLIN CANC R, 5(9), 1999, pp. 2366-2373
5. Blagosklonny, MV; Chuman, Y; Bergan, RC; Fojo, T
   Mitogen-activated protein kinase pathway is dispensable for microtubule-active drug-induced Raf-1/Bcl-2 phosphorylation and apoptosis in leukemia cells
   LEUKEMIA
   
   M.V. Blagosklonny et al., "Mitogen-activated protein kinase pathway is dispensable for microtubule-active drug-induced Raf-1/Bcl-2 phosphorylation and apoptosis in leukemia cells", LEUKEMIA, 13(7), 1999, pp. 1028-1036
6. SCHWARTZ GN; LIU YQ; TISDALE J; WALSHE K; FOWLER D; GRESS R; BERGAN RC
   GROWTH-INHIBITION OF CHRONIC MYELOGENOUS LEUKEMIA-CELLS BY ODN-1, AN APTAMERIC INHIBITOR OF P210(BCR-ABL) TYROSINE KINASE-ACTIVITY
   Antisense & nucleic acid drug development
   
   G.N. Schwartz et al., "GROWTH-INHIBITION OF CHRONIC MYELOGENOUS LEUKEMIA-CELLS BY ODN-1, AN APTAMERIC INHIBITOR OF P210(BCR-ABL) TYROSINE KINASE-ACTIVITY", Antisense & nucleic acid drug development, 8(4), 1998, pp. 329-339
7. THIBAULT A; FIGG WD; BERGAN RC; LUSH RM; MYERS CE; TOMPKINS A; REED E; SAMID D
   A PHASE-II STUDY OF 5-AZA-2'DEOXYCYTIDINE (DECITABINE) IN HORMONE-INDEPENDENT METASTATIC (D2) PROSTATE-CANCER
   Tumori
   
   A. Thibault et al., "A PHASE-II STUDY OF 5-AZA-2'DEOXYCYTIDINE (DECITABINE) IN HORMONE-INDEPENDENT METASTATIC (D2) PROSTATE-CANCER", Tumori, 84(1), 1998, pp. 87-89
8. ROHLFF C; BLAGOSKLONNY MV; KYLE E; KESARI A; KIM IY; ZELNER DJ; HAKIM F; TREPEL J; BERGAN RC
   PROSTATE-CANCER CELL-GROWTH INHIBITION BY TAMOXIFEN IS ASSOCIATED WITH INHIBITION OF PROTEIN-KINASE-C AND INDUCTION OF P21(WAF1 CIP1)/
   The Prostate
   
   C. Rohlff et al., "PROSTATE-CANCER CELL-GROWTH INHIBITION BY TAMOXIFEN IS ASSOCIATED WITH INHIBITION OF PROTEIN-KINASE-C AND INDUCTION OF P21(WAF1 CIP1)/", The Prostate, 37(1), 1998, pp. 51-59
9. BERGAN RC
   EX-VIVO BONE-MARROW PURGING WITH OLIGONUCLEOTIDES
   ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT
   
   R.C. Bergan, "EX-VIVO BONE-MARROW PURGING WITH OLIGONUCLEOTIDES", ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT, 7(3), 1997, pp. 251-255
10. DAWSON NA; FIGG WD; COOPER MR; SARTOR O; BERGAN RC; SENDEROWICZ AM; STEINBERG SM; TOMPKINS A; WEINBERGER B; SAUSVILLE EA; REED E; MYERS CE
    PHASE-II TRIAL OF SURAMIN, LEUPROLIDE, AND FLUTAMIDE IN PREVIOUSLY UNTREATED METASTATIC PROSTATE-CANCER
    Journal of clinical oncology
    
    N.A. Dawson et al., "PHASE-II TRIAL OF SURAMIN, LEUPROLIDE, AND FLUTAMIDE IN PREVIOUSLY UNTREATED METASTATIC PROSTATE-CANCER", Journal of clinical oncology, 15(4), 1997, pp. 1470-1477
11. BERGAN RC; WALLS RG; FIGG WD; DAWSON NA; HEADLEE D; TOMPKINS A; STEINBERG SM; REED E
    SIMILAR CLINICAL OUTCOMES IN AFRICAN-AMERICAN AND NON-AFRICAN-AMERICAN MALES TREATED WITH SURAMIN FOR METASTATIC PROSTATE-CANCER
    Journal of the National Medical Association
    
    R.C. Bergan et al., "SIMILAR CLINICAL OUTCOMES IN AFRICAN-AMERICAN AND NON-AFRICAN-AMERICAN MALES TREATED WITH SURAMIN FOR METASTATIC PROSTATE-CANCER", Journal of the National Medical Association, 89(9), 1997, pp. 622-628
12. BERGAN RC; KYLE E; CONNELL Y; NECKERS L
    INHIBITION OF PROTEIN-TYROSINE KINASE-ACTIVITY IN INTACT-CELLS BY THEAPTAMERIC ACTION OF OLIGODEOXYNUCLEOTIDES
    Antisense research and development
    
    R.C. Bergan et al., "INHIBITION OF PROTEIN-TYROSINE KINASE-ACTIVITY IN INTACT-CELLS BY THEAPTAMERIC ACTION OF OLIGODEOXYNUCLEOTIDES", Antisense research and development, 5(1), 1995, pp. 33-38
13. DAWSON NA; COOPER MR; FIGG WD; HEADLEE DJ; THIBAULT A; BERGAN RC; STEINBERG SM; SAUSVILLE EA; MYERS CE; SARTOR O
    ANTITUMOR-ACTIVITY OF SURAMIN IN HORMONE-REFRACTORY PROSTATE-CANCER CONTROLLING FOR HYDROCORTISONE TREATMENT AND FLUTAMIDE WITHDRAWAL AS POTENTIALLY CONFOUNDING VARIABLES
    Cancer
    
    N.A. Dawson et al., "ANTITUMOR-ACTIVITY OF SURAMIN IN HORMONE-REFRACTORY PROSTATE-CANCER CONTROLLING FOR HYDROCORTISONE TREATMENT AND FLUTAMIDE WITHDRAWAL AS POTENTIALLY CONFOUNDING VARIABLES", Cancer, 76(3), 1995, pp. 453-462
14. FIGG WD; SARTOR O; COOPER MR; THIBAULT A; BERGAN RC; DAWSON N; REED E; MYERS CE
    PROSTATE-SPECIFIC ANTIGEN DECLINE FOLLOWING THE DISCONTINUATION OF FLUTAMIDE IN PATIENTS WITH STAGE D2 PROSTATE-CANCER
    The American journal of medicine
    
    W.D. Figg et al., "PROSTATE-SPECIFIC ANTIGEN DECLINE FOLLOWING THE DISCONTINUATION OF FLUTAMIDE IN PATIENTS WITH STAGE D2 PROSTATE-CANCER", The American journal of medicine, 98(4), 1995, pp. 412-414
15. BERGAN RC; KYLE E; NECKERS L
    GENISTEIN - A PROTEIN-TYROSINE KINASE INHIBITOR INHIBITS THE GROWTH OF PROSTATE-CANCER CELLS
    Journal of cellular biochemistry
    
    R.C. Bergan et al., "GENISTEIN - A PROTEIN-TYROSINE KINASE INHIBITOR INHIBITS THE GROWTH OF PROSTATE-CANCER CELLS", Journal of cellular biochemistry, 1994, pp. 251-251
16. BERGAN RC; CONNEL Y; FAHMY B; KYLE E; NECKERS L
    SYNTHETIC OLIGONUCLEOTIDES - POTENT APTAMERIC INHIBITORS OF PROTEIN TYROSINE KINASES
    Journal of cellular biochemistry
    
    R.C. Bergan et al., "SYNTHETIC OLIGONUCLEOTIDES - POTENT APTAMERIC INHIBITORS OF PROTEIN TYROSINE KINASES", Journal of cellular biochemistry, 1993, pp. 210-210